Safety and Tolerability Study of Oral NS-018 in Patients With Primary Myelofibrosis (MF), Post-polycythemia Vera MF or Post-essential Thrombocythemia MF
NS Pharma, Inc.
NS Pharma, Inc.
Novartis
Mayo Clinic
Italfarmaco
Incyte Corporation
OHSU Knight Cancer Institute
UNC Lineberger Comprehensive Cancer Center